SciBase Holding ABOMXSTO: SCIB

Interim report

· Issued by SciBase Holding AB

Summary by 6ix AI

SciBase Holding AB, a Swedish medical technology company that sells the Nevisense skin assessment system, reported net sales of TSEK 14,621 (thousand Swedish kronor) for the third quarter ended September 30, 2026, up from TSEK 10,339 a year earlier. Its loss after tax was TSEK 25,768, compared with TSEK 18,170.

Key details

  • For January 1 to September 30, 2026, net sales were TSEK 44,207 (TSEK 27,987 a year earlier), the loss after tax was TSEK 77,478 (TSEK 61,763) and cash flow from operations was negative TSEK 81,667. Cash equivalents were TSEK 13,532 at September 30, 2026.
  • Third-quarter gross margin was 72.3% (69.5%). SciBase says currency, a higher gold price and investment to ramp up production weighed on it. Electrode sales rose 36% to 28,896 units. Loss per share was SEK 2.52 (SEK 4.66), with share figures recalculated for a 1-for-100 reverse share split in June 2026.
  • During the quarter SciBase filed a 510(k) premarket notification, a request for US clearance, with the U.S. Food and Drug Administration (FDA). It seeks to expand the US approved use of Nevisense to include assessment of non-melanoma skin cancers.
  • Also during the quarter, SciBase expanded its collaboration with Castle Biosciences and received an additional order of approximately SEK 5 million for an additional clinical study. The Board decided on a fully underwritten rights offering of around MSEK 57.5 (million Swedish kronor) before issue costs.
  • After the period, SciBase and Nevisense secured first US payer coverage with a major insurance company. A new study led by the US National Institute of Health (NIH) with the Swiss Institute of Allergy and Asthma Research will use Nevisense as a primary endpoint to explore how environmental exposure affects the skin.

What’s still pending

  • The FDA 510(k) submission to expand the US use of Nevisense is pending.
  • The NIH-led study has not yet started; SciBase says it will be initiated.

6ix AI wrote this summary from the release below and checked it against the release.

English Published: 2026-11-12 08:00:00 CET Scibase Holding AB - Interim report (Q1 and Q3) Interim report

January 1 - September 30, 2026

The third quarter in figures

  • Net sales were TSEK 14,621 (10,339), +41%, cleared for currency effects +45%.
  • The loss after tax was TSEK 25,768 (18,170).
  • The loss per share was SEK 2.52 (4.66).
  • The cash flow from current operations was negative in the amount of TSEK 21,999 (17,287).
  • The gross margin was 72,3% (69.5%).
  • Electrode sales volume increased by 36% and was 28,896 (21,278) units. Repeat sales of electrodes to existing customers increased by 40%.

The first nine months in figures

  • Net sales were TSEK 44,207 (27,987), +58%, cleared for currency effects +64%.
  • The loss after tax was TSEK 77,478 (61,763).
  • The loss per share was SEK 8.11 (18,04).
  • The cash flow from current operations was negative in the amount of TSEK 81,667 (63,754).
  • The gross margin was 58.0% (68.8%).
  • Electrode sales volume increased by 73% and was 99,500 (57,546) units. Repeat sales of electrodes to existing customers increased by 76% (incl deliveries to Castle).

Important events during the quarter

  • Overall sales increased by 41% (+45%, before currency effects). Sales in Germany within the skin cancer segment increased by 18% vs Q2-25 (increased by 19% in local currency). Sales in the US skin cancer market increased by 68% (66% in local currency) while the sales within the skin barrier segment increased by 286%.
  • The gross margin was negatively affected in the quarter by currency development (negative impact of around 0.6%), increased gold price and continued investments to ramp up production which has been balanced by implementation of improvements in production. Cleared for currency effects the margin was around 73%.
  • SciBase submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking to expand the U.S. indication for Nevisense to include the assessment of Non-Melanoma Skin Cancers (keratinocyte skin cancers).
  • SciBase announced an expanded collaboration with Castle Biosciences, received an additional order of approximately SEK 5 million for an additional clinical study.
  • The Board decided on a fully underwritten rights offering of around MSEK 57.5 before issue costs.
  • SciBase announced changes in senior management.

Important events after the end of the period

  • SciBase and Nevisense secured first US payer coverage with major insurance company. For a medtech company, this is one of the milestones that matters most: it means insurers now recognize the company's non-invasive skin assessment technology as a covered, reimbursable procedure.
  • SciBase announced the outcome of the rights issue.
  • SciBase announcedthat a new study will be initiated in a collaboration between NIH (National Institute of Health, US) and the Swiss Institute of Allergy and Asthma Research (SIAF). In the NIH led study - THREAT (Testing Harms Related to Exposure to Allergenic Toxins), SciBase Nevisense and its Electrical Impedance Spectroscopy (EIS) technology will be used as a primary endpoint to explore how environmental exposure impacts the skin.

Financial overview

July 1, 2025 -
July 1 - Sep 30Jan 1 - Sep 30Sep 30, 2026Jan 1 - Dec 31
THE GROUP2026202520262025Rolling-122025
Net sales, SEK ths14 62110 33944 20727 98756 68240 461
Gross margin, %72,3%69,5%58,0%68,8%59,1%67,0%
Equity/Asset ratio, %10,6%62,0%10,6%62,0%36,4%12,8%
Net indebtness, multiple8,470,6112,230,611,746,84
Cash equivalents, SEK ths13 53224 75713 53224 75713 53222 604
Cashflow from operating activities, SEK ths-21 999-17 287-81 667-63 754-102 492-84 579
Earnings per share (before and after dilution), SEK*-2,52-4,66-8,11-18,04-12,54-24,16
Shareholder's equity per share, SEK*0,558,580,599,782,961,85
Average number of shares, 000'*10 2253 9029 5493 4246 6173 604
Number of shares at closing of period, 000'*10 2254 14210 2254 14210 2254 142
Share price at end of period, SEK*15,9038,0015,9038,0015,9029,00
Number of sold electrodes, pieces28 89621 27899 50057 546128 13486 180
Average number of employees503449354837
*Recalculated for in June 2026 performed reverse split, 1:100.

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on November 12, 2026.

This report has been comprehensively reviewed by the Company's auditors.

Contact person:

Michael Colérus, CFO, +46 70 341 34 72, e-mail: michael.colerus@scibase.com

For additional information, please contact:

Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Certified Advisor (CA):
DNB Carnegie Investment Bank AB (publ)
Tel: +46 8 588 68 570
Email: certifiedadviser@carnegie.se

About SciBase and Nevisense
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

11118066.pdf https://attachment.news.eu.nasdaq.com/a35aee2de3d7fdcf66dfaa006f6e19139
Company News Subscribe European Market Activity Nasdaq Europe
© 2026, Nasdaq, Inc. All Rights Reserved.

SciBase Holding AB on 6ix

Story so far

Earlier from SciBase

All SciBase news releases